Skip to main content
SpringerLink
Log in

Targeting Angiogenesis in Malignant Pleural Mesothelioma

  • Chapter
  • First Online:
Mesothelioma

  • 500 Accesses

Abstract

Malignant pleural mesothelioma (MPM) is a quite rare cancer but with increasing incidence worldwide, usually associated with previous asbestos exposure. MPM patients have globally a poor prognosis with limited therapeutic options and no validated curative treatment. Therefore, innovative drugs and strategies are needed. Based on the preclinical rationale and first-trial data, antiangiogenic drugs have been tested in MPM, mostly associated with standard frontline chemotherapy (cisplatin/pemetrexed). However, if anti-VEGF antibody (bevacizumab) exhibited a real value in addition with first-line chemotherapy in a large phase III trial, other drugs’ and trials’ results did not support the use of this class of targeted therapies so far. Moreover, there are no biomarkers to date to predict the efficacy of antiangiogenic drugs in MPM patients. Future directions include the evaluation of antiangiogenic drugs in combination with immunotherapy in MPM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–6.

    PubMed  PubMed Central  Google Scholar 

  2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397–408.

    Article  CAS  PubMed  Google Scholar 

  3. Andujar P, Lacourt A, Brochard P, Pairon J-C, Jaurand M-C, Jean D. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. J Toxicol Environ Health B Crit Rev. 2016;19(5–6):151–72.

    Article  CAS  PubMed  Google Scholar 

  4. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–95.

    Article  CAS  PubMed  Google Scholar 

  5. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v31–9.

    Article  PubMed  Google Scholar 

  6. van Zandwijk N, Clarke C, Henderson D, Musk W, Fong K, Nowak AK, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.

    PubMed  PubMed Central  Google Scholar 

  7. Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73:i1–i30.

    Article  PubMed  Google Scholar 

  8. Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343–73.

    Article  PubMed  Google Scholar 

  9. NCCN Malignant pleural mesothelioma guidelines. Version 2.2018 — February 26, 2018. https://www.nccn.org/professionals/physician_gls/pdf/mpm_blocks.pdf. Accessed 09 Sept 2018.

  10. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.

    Article  CAS  PubMed  Google Scholar 

  11. Scherpereel A, Mazieres J, Greillier L, Gervais R, Bylicki O, Monnet I, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol. 2017;35(18_suppl):LBA8507.

    Article  Google Scholar 

  12. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collov E, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75(3):360–7.

    Article  CAS  PubMed  Google Scholar 

  13. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  CAS  PubMed  Google Scholar 

  14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6.

    Article  CAS  PubMed  Google Scholar 

  15. Levin PA, Dowell JE. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther. 2017;10:2057–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hendry SA, Farnsworth RH, Solomon B, et al. The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 2016;7:621.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Li C, Liu T, Bazhin AV, Yang Y. The sabotaging role of myeloid cells in anti-angiogenic therapy: coordination of angiogenesis and immune suppression by hypoxia. J Cell Physiol. 2017;232(9):2312–22.

    Article  CAS  PubMed  Google Scholar 

  18. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 1999;189(1):72–8.

    Article  CAS  PubMed  Google Scholar 

  19. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer. 2001;85(6):863–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999;81(1):54–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Soini Y, Puhakka A, Kahlos K, et al. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. Histopathology. 2001;39(2):179–86.

    Article  CAS  PubMed  Google Scholar 

  22. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32(12):1095–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161–e72.

    Article  CAS  PubMed  Google Scholar 

  24. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14.

    Article  CAS  PubMed  Google Scholar 

  25. Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013;14(6):543–51.

    Article  CAS  PubMed  Google Scholar 

  26. Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P. A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol. 2016;11(5):758–68.

    Article  PubMed  Google Scholar 

  27. Tsao AS, Moon J, Wistuba I, Vogelzang NJ, Kalemkerian G, Redman M, et al. Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2017;12(8):1299–308.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tsao AS, Miao J, Wistuba I, Vogelzang NJ, Heymach J, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel SM, Weber Redman M, Gandara DR, Kelly K. SWOG S0905: a randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. Abstract ASCO 2018. J Clin Oncol. 2018;36(suppl):abstr 8514.

    Article  Google Scholar 

  29. Grosso F, Steele N, Novello S, Kowak AK, Popat S, Greillier L, et al. Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-meso trial. J Clin Oncol. 2017;35:3591–600.

    Article  CAS  PubMed  Google Scholar 

  30. Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013;8(6):783–7.

    Article  CAS  PubMed  Google Scholar 

  31. Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, et al. A phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia group B 30307. J Thorac Oncol. 2010;5(10):1655–61.

    Article  PubMed  Google Scholar 

  32. Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, et al. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014;15(3):197–201.

    Article  CAS  PubMed  Google Scholar 

  33. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113(4):808–14.

    Article  CAS  PubMed  Google Scholar 

  34. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475–88.

    Article  CAS  PubMed  Google Scholar 

  35. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30(20):2509–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004–11.

    Article  CAS  PubMed  Google Scholar 

  37. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109(3):552–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012;77(3):567–71.

    Article  PubMed  Google Scholar 

  40. Westeel V, Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Morin F, Zalcman G, French Cooperative Thoracic Intergroup (IFCT). Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial. J Clin Oncol. 2018;36(suppl):abstr 8505.

    Article  Google Scholar 

  41. Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? Eur Respir Rev. 2018;27(147):170098.

    Article  PubMed  Google Scholar 

  42. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer. 2005;48:291–6.

    Article  PubMed  Google Scholar 

  43. Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M, IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pulmonary and Thoracic Oncology Department, Univ Lille, CHU Lille, Lille, France

    Arnaud Scherpereel

  2. French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN), Lille, France

    Arnaud Scherpereel

Authors
  1. Arnaud Scherpereel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnaud Scherpereel .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Giovanni Luca Ceresoli

  2. Scientific Direction, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Emilio Bombardieri

  3. Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy

    Maurizio D'Incalci

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Scherpereel, A. (2019). Targeting Angiogenesis in Malignant Pleural Mesothelioma. In: Ceresoli, G., Bombardieri, E., D'Incalci, M. (eds) Mesothelioma. Springer, Cham. https://doi.org/10.1007/978-3-030-16884-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16884-1_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16883-4

  • Online ISBN: 978-3-030-16884-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation